



1. Statement of Audited Results for the Quarter and Year Ended March 31, 2017

(Rs. in Lakhs except earnings per share)

Particulars	Quarter ended			Year Ended	Year Ended
	March 31, 2017	December 31, 2016	March 31, 2016	March 31, 2017	March 31, 2016
	Audited	Unaudited	Audited	Audited	Audited
	Refer Note 3		Refer Note 3		
1 Income from Operations					
(a) Revenue from operations (Gross)	715,42	755,72	689,86	2938,69	2645,64
(b) Other income	15,45	13,90	12,53	57,64	50,59
Total Income	730,87	769,62	702,39	2996,33	2696,23
2 Expenses					
(a) Cost of materials consumed	71,73	76,39	72,72	315,94	312,78
(b) Purchases of stock-in-trade	269,97	428,95	250,45	1497,56	1164,38
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	80,62	(64,70)	72,67	(101,44)	14,87
(d) Excise duty on sales	6,32	11,62	6,03	36,13	31,14
(e) Employee benefits expense	84,76	87,85	80,44	345,27	341,09
(f) Finance cost	2,00	1	2,01	2,04	2,52
(g) Depreciation and amortisation expense	3,84	4,35	4,11	16,43	14,44
(h) Other expenses	139,15	92,55	123,29	447,91	417,00
Total Expenses	658,39	637,02	611,72	2559,84	2298,22
3 Profit before tax (1-2)	72,48	132,60	90,67	436,49	398,01
4 Tax expense					
(a) Current tax expense	26,77	47,15	33,52	156,88	143,72
(b) Tax adjustment for earlier years	4,96	-	-	4,96	42
(c) Deferred tax (Credit)	(1,31)	(11)	(1,84)	(2,00)	(1,38)
Total Tax expenses	30,42	47,04	31,68	159,84	142,76
5 Net Profit for the period (3-4)	42,06	85,56	58,99	276,65	255,25
6 Other Comprehensive Income					
- Items that will not be reclassified to Profit or Loss	(2,87)	-	(38)	(2,87)	(1,53)
- Income tax relating to above items	99	-	13	99	53
Total Other Comprehensive Income, net of tax	(1,88)	-	(25)	(1,88)	(1,00)
7 Total Comprehensive Income for the period (5+6)	40,18	85,56	58,74	274,77	254,25
8 Paid-up Equity Share Capital (Face Value Rs.10 per Equity Share)	21,25	21,25	21,25	21,25	21,25
9 Earnings per equity share - Basic/Diluted (of Rs. 10/- each) (not annualised)	19.79	40.26	27.76	130.19	120.12

SIGNED FOR IDENTIFICATION
BY
*
S R B C & CO LLP
MUMBAI

Indratim

Duey An

2. Statement of Assets and Liabilities

(Rs. in Lakhs)

	As at March 31, 2017	As at March 31, 2016
	Audited	Audited
Assets		
Non-current assets		
Property, plant and equipment	107,65	105,89
Capital work-in-progress	5,14	1,91
Other Intangible assets	1,95	2,56
Intangible assets under development	1,13	,93
Financial assets		
- Loans	5,86	6,21
- Other financial assets	21,19	13,25
Deferred tax assets (Net)	12,38	9,39
Other non-current assets	17,95	25,74
Total Non-current assets	173,25	165,88
Current assets		
Inventories	500,63	370,10
Financial assets		
- Trade receivables	174,22	145,02
- Cash and cash equivalents	202,24	140,19
- Bank balances other than cash and cash equivalents	888,68	699,23
- Loans	1,62	2,09
- Other financial assets	38,76	27,74
Current Tax Assets (Net)	13,19	12,91
Other current assets	71,21	53,35
Total Current assets	1890,55	1450,63
Total Assets	2063,80	1616,51
Equity and liabilities		
Equity		
Equity Share capital	21,25	21,25
Other equity	1365,69	1174,35
Total Equity	1386,94	1195,60
Non-current liabilities		
Provisions	47,22	38,64
Total Non-current liabilities	47,22	38,64
Current liabilities		
Financial liabilities		
- Trade payables	474,69	230,14
- Other financial liabilities	41,06	52,50
Other current liabilities	34,84	34,40
Provisions	70,39	59,91
Current tax liabilities (net)	8,66	5,32
Total Current liabilities	629,64	382,27
Total equity and liabilities	2063,80	1616,51

SIGNED FOR IDENTIFICATION
BY

S R B C & CO LLP
MUMBAI



Notes :

- 1 The above financial results have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on May 19, 2017.
- 2 This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated July 5, 2016. The impact of transition has been accounted for in opening reserves and the comparative period results have been restated. Accordingly, the figures for corresponding quarter and year ended March 31, 2016 have been presented after incorporating the applicable Ind AS adjustments.
- 3 The figures for the quarter ended March 31, 2017 and quarter ended March 31, 2016 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the relevant financial year which were only reviewed and not subjected to audit.
- 4 The Company has only one segment which is " Pharmaceuticals". Therefore disclosure relating to segments is not applicable and accordingly not made.
- 5 Reconciliation between financial results as previously reported under previously applicable Indian GAAP and Ind AS for the quarter and year ended March 31, 2016 is as below :

	(Rs. in Lakhs)	
	Quarter ended March 31, 2016	Year ended March 31, 2016
Net Profit under Previous GAAP	59,00	259,63
Add/(Less) : Adjustments of		
Cost of employee share based payments	(46)	(5,63)
Actuarial loss on employee defined benefit funds recognized in Other Comprehensive Income	38	1,53
Physicians samples written off	(15)	(3)
Discounting on fair valuation of provisions	(35)	(35)
Others	78	76
Deferred Tax impact on Ind AS adjustments	(21)	(66)
Net Profit for the period under Ind AS	58,99	255,25
Other Comprehensive Income (after Tax)	(25)	(1,00)
Total Comprehensive Income for the period	58,74	254,25

- 6 Reconciliation of Equity as on March 31, 2016 as previously applicable Indian GAAP to Ind AS is as below :

	(Rs. in Lakhs)
	Year ended March 31, 2016
Equity under Previous GAAP	1086,39
Add/(Less) : Adjustments of	
Proposed dividend and dividend distribution tax	89,51
Changes related to physician samples	(5,94)
Discounting on fair valuation of provisions	2,85
Others	73
Deferred Tax on Ind AS adjustments	81
Equity under Ind AS	1174,35

- 7 The Board of Directors of the Company have recommended a final dividend of Rs.40 per equity share (nominal value Rs.10 per equity share) amounting to Rs.85,00 lakhs subject to approval of members at the ensuing Annual General Meeting of the Company.
- 8 Figures for the previous periods have been regrouped/reclassified wherever considered necessary.



For and on behalf of the Board of Directors of
Abbott India Limited

Ambati Venu
Managing Director
DIN : 07614849

Place : Mumbai
Date : May 19, 2017

Deep An